AVEO Pharmaceuticals, Inc. (AVEO) Reports In-Line Q3 Loss; Revs Light

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) reported Q3 loss of ($0.55), in-line with the analyst estimate of ($0.55). Revenue for the quarter came in at $3.59 million versus the consensus estimate of $7.13 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance